MYUNGMOON Pharm co.,Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 13, 2022 at 09:30 pm EST
Share
MYUNGMOON Pharm co.,Ltd reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was KRW 2,209.14 million compared to KRW 2,007.59 million a year ago. Net income was KRW 93.93 million compared to net loss of KRW 133.82 million a year ago. Basic earnings per share from continuing operations was KRW 3 compared to basic loss per share from continuing operations of KRW 4 a year ago. Basic earnings per share was KRW 3 compared to basic loss per share of KRW 4 a year ago.
For the nine months, sales was KRW 6,372.39 million compared to KRW 5,324.23 million a year ago. Net income was KRW 3,235.24 million compared to KRW 1,140.73 million a year ago. Basic earnings per share from continuing operations was KRW 96 compared to KRW 34 a year ago. Basic earnings per share was KRW 96 compared to KRW 34 a year ago.
MyungMoon Pharm. Co., Ltd. is a Korea-based company mainly engaged in the manufacture of pharmaceuticals. Its products include ethical (ETC) drugs and over the counter (OTC) drugs. Its ETC drugs include anesthetic agents, digestive system drugs, rheumatoid arthritis remedies, central nervous system drugs, circulatory drugs, anti-depressant agents, anti-diabetic agents, antibiotics, hormone agents, narcotics and drugs for dermatology systems. Its OTC drugs include antinauseant agents, hepatic agents, immunologic agents, antidiarrheal agents, skin external preparations, antiallergic agents, muscle relaxants, cold drugs and parasiticides. The Company is also involved in the operation golf courses. January 2, 2012, the Company completed the merger with its wholly owned subsidiary.